<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054468</url>
  </required_header>
  <id_info>
    <org_study_id>ROSANNA</org_study_id>
    <nct_id>NCT02054468</nct_id>
  </id_info>
  <brief_title>Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia</brief_title>
  <acronym>ROSANNA</acronym>
  <official_title>Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the effective-doses ED-50 and ED-95 (the doses required
      for a 50% and 95% twitch inhibition, respectively) of the non-depolarizing muscle relaxant
      rocuronium after single-shot or steady-state propofol anesthesia in a clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuromuscular blocking agents are worldwide used as a standard component of a modern balanced
      anesthesia regime. They are administered to facilitate tracheal intubation, reduce laryngeal
      trauma and optimize surgical conditions. The dose usually recommended to facilitate tracheal
      intubation approximates at least two times the drug´s effective dose ED-95 (the dose required
      for a 95% effect) depending on the choice of the neuromuscular blocking agent. This overdose
      is administered to induce a very deep paralysis with a fast onset of action providing
      clinically acceptable intubating conditions. Moreover, our clinical experience has shown that
      the dose-relationship of a neuromuscular blocking agents estimated during steady-state
      anesthesia does not necessarily correlate with the dose-response curve of the same drug
      during anesthetic induction. Therefore, a discrepancy between the applied dose and the
      clinical outcome measure, the intubating conditions, becomes apparent. This might be related
      to effects of the co-administered anesthetics at the neuromuscular junction. While inhaled
      anesthetics augment the paralyzing effects of non-depolarizering muscle relaxants in a
      dose-dependent fashion and depend on the duration of anesthesia, little is known about the
      interactions of the intravenous anesthetic propofol with the non-depolarizing blocking agent
      rocuronium. We hypothesize that the intravenous administration of propofol also influences
      the potency of rocuronium dependant on the duration of its application.

      This study, therefore, is designed to determine the dose-response relationship of rocuronium
      after single-shot or steady-state propofol anesthesia in a clinical setting. The primary
      endpoints are the ED-50s and ED-95s of rocuronium during anesthetic induction with a
      single-shot propofol and after 30minutes of steady-state propofol anesthesia. The secondary
      endpoints are the slopes and the intercepts of the respective dose-response-curves, the onset
      and duration of muscle paralysis and the recovery from neuromuscular blockade.

      Materials &amp; Methods

      We will investigate patients scheduled for elective low-risk surgical procedures under
      general anesthesia. Patients will be allocated to two experimental groups. After
      neuromuscular monitoring is established under remifentanil infusion, patients of the group
      &quot;Induction&quot; will receive a single-shot propofol followed by injection of rocuronium and
      endotracheal intubation. Patients of the group &quot;Maintenance&quot; will be anaesthetized with an
      induction dose of propofol followed by 30 minutes of total intravenous anesthesia (TIVA:
      propofol/ remifentanil) before rocuronium is administered. Airway will be managed using a
      laryngeal mask or tracheal intubation.

      During surgery, anesthesia will be maintained with TIVA. Onset and duration of neuromuscular
      blockade and spontaneous recovery will be monitored with electromyography.

      Postoperatively, patients will be monitored for 60 minutes in our post-anesthesia care unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ED-50 of rocuronium</measure>
    <time_frame>Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min</time_frame>
    <description>The primary outcome measure is the 1) ED-50 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-95 of rocuronium</measure>
    <time_frame>Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min</time_frame>
    <description>The primary outcome measure is 2) the ED-95 of rocuronium during anesthesia induction with propofol and after steady-state propofol anesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of rocuronium (composite outcome measure)</measure>
    <time_frame>Anesthesia time during their surgical procedure (=arrival in the OR until discharge from the post-anesthesia care unit), ca. 180min</time_frame>
    <description>The secondary outcome measures are the slopes and the intercepts of the dose-response-curves for rocuronium, the onset and duration of muscle paralysis and the recovery from neuromuscular blockade.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single-Shot Propofol</intervention_name>
    <description>Single-shot propofol induction dose (1.5-2.5mg/kg body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <other_name>2,6-Diisopropylphenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30min infusion Propofol</intervention_name>
    <description>30min of propofol infusion (4-6mg/kg/h)</description>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>2,6-Diisopropylphenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil infusion</intervention_name>
    <description>Remifentanil infusion (0.1-0.2µg/kg/min)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Ultiva®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.07mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.07mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.1mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.1mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.15mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.15mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.2mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.2mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.3mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.3mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (0.45mg/kg/body mass)</intervention_name>
    <description>Rocuronium (0.45mg/kg/body mass)</description>
    <arm_group_label>Single-shot-Propofol &amp; Remifentanil</arm_group_label>
    <arm_group_label>30min infusion Propofol &amp; Remifentanil</arm_group_label>
    <other_name>Esmeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients scheduled for a low risk-surgical procedure under general anesthesia

          2. Patients ASA physical status I-III

          3. Patients older than 18years

          4. Patients having given informed consent to the study

        Exclusion Criteria:

          1. Patients who decline to give informed consent to the study

          2. Known or suspected allergy towards anesthetics or rocuronium

          3. Pregnant and breastfeeding women

          4. Known or suspected neuromuscular disease

          5. Burn injury prior to the investigation

          6. Anatomic and functional malformations with expected difficult intubation

          7. Anorexia, Bulimia nervosa, Malnutrition

          8. Heart failure

          9. Use of drugs that interfere with muscle relaxant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Blobner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Naguib M, Seraj M, Abdulrazik E. Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, enflurane, isoflurane, and halothane anesthesia in surgical patients. Anesth Analg. 1992 Aug;75(2):193-7.</citation>
    <PMID>1321569</PMID>
  </reference>
  <reference>
    <citation>Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979 Jun;50(6):539-41.</citation>
    <PMID>156513</PMID>
  </reference>
  <reference>
    <citation>Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003 May;98(5):1042-8.</citation>
    <PMID>12717123</PMID>
  </reference>
  <reference>
    <citation>Eikermann M, Blobner M, Groeben H, Rex C, Grote T, Neuhäuser M, Beiderlinden M, Peters J. Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg. 2006 Mar;102(3):937-42.</citation>
    <PMID>16492855</PMID>
  </reference>
  <reference>
    <citation>Hemmerling TM, Le N, Decarie P, Cousineau J, Bracco D. Total intravenous anesthesia with propofol augments the potency of mivacurium. Can J Anaesth. 2008 Jun;55(6):351-7. doi: 10.1007/BF03021490.</citation>
    <PMID>18566198</PMID>
  </reference>
  <reference>
    <citation>Robertson EN, Fragen RJ, Booij LH, van Egmond J, Crul JF. Some effects of diisopropyl phenol (ICI 35 868) on the pharmacodynamics of atracurium and vecuronium in anaesthetized man. Br J Anaesth. 1983 Aug;55(8):723-8.</citation>
    <PMID>6136286</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle relaxant, Rocuronium, TIVA, Propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

